^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TheraCIM (nimotuzumab)

    i
    Company:
    Biocon, Daiichi Sankyo, Oncoscience
    Drug class:
    EGFR inhibitor
    Related drugs:
    Apply
    Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer (NCT05278728)
    Phase 1/2
    Biotech Pharmaceutical Co., Ltd.
    Completed
    Last update posted :
    02/07/2025
    Initiation :
    07/01/2009
    Primary completion :
    08/01/2013
    Completion :
    12/01/2013
    KRAS • RAS
    |
    irinotecan • TheraCIM (nimotuzumab)
    HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients (NCT06770452)
    Phase 2
    Zhejiang University
    Not yet recruiting
    Last update posted :
    01/13/2025
    Initiation :
    02/01/2025
    Primary completion :
    02/01/2027
    Completion :
    02/01/2028
    KRAS
    |
    gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • HRS-4642
    A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer (NCT02395016)
    Phase 3
    Biotech Pharmaceutical Co., Ltd.
    Completed
    Last update posted :
    04/04/2024
    Initiation :
    04/01/2015
    Primary completion :
    11/01/2021
    Completion :
    11/01/2021
    KRAS • RAS
    |
    KRAS mutation • RAS mutation
    |
    gemcitabine • TheraCIM (nimotuzumab)
    Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer (NOTABLE-308) (NCT06343116)
    Phase 3
    Biotech Pharmaceutical Co., Ltd.
    Not yet recruiting
    Last update posted :
    04/02/2024
    Initiation :
    04/01/2024
    Primary completion :
    04/01/2027
    Completion :
    04/01/2027
    EGFR
    |
    Lonsurf (trifluridine/tipiracil) • TheraCIM (nimotuzumab)
    Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer (NCT02947386)
    Phase 1/2
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    10/05/2023
    Initiation :
    06/29/2017
    Primary completion :
    04/15/2021
    Completion :
    09/08/2022
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression • EGFR mutation • EGFR expression • ALK rearrangement
    |
    Opdivo (nivolumab) • TheraCIM (nimotuzumab)
    Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age (NCT06048913)
    Phase 1
    The First Affiliated Hospital with Nanjing Medi...
    Enrolling by invitation
    Last update posted :
    09/21/2023
    Initiation :
    07/01/2022
    Primary completion :
    07/01/2025
    Completion :
    07/01/2028
    EGFR
    |
    EGFR expression
    |
    TheraCIM (nimotuzumab)
    Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors (NCT06022276)
    Phase N/A
    Tianjin Medical University Second Hospital
    Recruiting
    Last update posted :
    09/01/2023
    Initiation :
    12/01/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    EGFR
    |
    EGFR amplification • CDKN2A negative
    |
    TheraCIM (nimotuzumab)
    Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (NOTABLE-307) (NCT05978050)
    Phase 3
    Biotech Pharmaceutical Co., Ltd.
    Not yet recruiting
    Last update posted :
    08/07/2023
    Initiation :
    09/01/2023
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    EGFR
    |
    EGFR expression • EGFR overexpression
    |
    paclitaxel • TheraCIM (nimotuzumab)
    Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy (NCT05803915)
    Phase 2
    Peking Union Medical College Hospital
    Not yet recruiting
    Last update posted :
    04/07/2023
    Initiation :
    05/01/2023
    Primary completion :
    09/30/2024
    Completion :
    03/10/2026
    PD-L1
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • TheraCIM (nimotuzumab)
    Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy (NCT05772208)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    03/16/2023
    Initiation :
    01/01/2022
    Primary completion :
    01/01/2025
    Completion :
    01/01/2028
    EGFR
    |
    cisplatin • AiRuiKa (camrelizumab) • TheraCIM (nimotuzumab)
    Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma (NCT03837808)
    Phase 3
    Sun Yat-sen University
    Recruiting
    Last update posted :
    11/07/2022
    Initiation :
    04/11/2019
    Primary completion :
    02/11/2024
    Completion :
    02/11/2024
    EGFR
    |
    EGFR expression • EGFR positive
    |
    cisplatin • TheraCIM (nimotuzumab)
    Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma (NCT05508347)
    Phase 2
    Sichuan Cancer Hospital and Research Institute
    Recruiting
    Last update posted :
    08/19/2022
    Initiation :
    08/15/2022
    Primary completion :
    09/15/2023
    Completion :
    09/15/2023
    EGFR
    |
    docetaxel • TheraCIM (nimotuzumab)
    Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC (NCT05351762)
    Phase 2
    Xijing Hospital
    Not yet recruiting
    Last update posted :
    07/04/2022
    Initiation :
    07/01/2022
    Primary completion :
    05/30/2024
    Completion :
    07/30/2024
    EGFR
    |
    EGFR expression • EGFR positive • CDKN2A negative
    |
    albumin-bound paclitaxel • Aqupla (nedaplatin) • TheraCIM (nimotuzumab)
    Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms (NCT05316480)
    Phase 2
    Fudan University
    Not yet recruiting
    Last update posted :
    04/07/2022
    Initiation :
    05/01/2022
    Primary completion :
    04/30/2025
    Completion :
    12/30/2026
    EGFR
    |
    EGFR overexpression
    |
    TheraCIM (nimotuzumab)
    H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study (NCT05167643)
    Phase N/A
    Tianjin Medical University Cancer Institute and...
    Recruiting
    Last update posted :
    04/07/2022
    Initiation :
    01/23/2022
    Primary completion :
    10/23/2022
    Completion :
    08/23/2024
    HER-2 • ER • PGR
    |
    HER-2 positive • ER positive • HR positive • PGR positive • HR positive + HER-2 positive
    |
    anastrozole • TheraCIM (nimotuzumab)
    Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma (NCT04223024)
    Phase 2
    Sun Yat-sen University
    Active, not recruiting
    Last update posted :
    12/06/2021
    Initiation :
    12/12/2019
    Primary completion :
    12/01/2022
    Completion :
    12/01/2026
    EGFR
    |
    EGFR expression
    |
    cisplatin • TheraCIM (nimotuzumab)
    Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma (NCT04456322)
    Phase 3
    Sun Yat-sen University
    Recruiting
    Last update posted :
    11/05/2021
    Initiation :
    07/06/2020
    Primary completion :
    06/01/2023
    Completion :
    06/01/2025
    EGFR
    |
    EGFR expression
    |
    cisplatin • TheraCIM (nimotuzumab)
    Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery (NCT05024019)
    Phase 2
    Eye & ENT Hospital of Fudan University
    Not yet recruiting
    Last update posted :
    08/27/2021
    Initiation :
    08/21/2021
    Primary completion :
    08/21/2025
    Completion :
    08/21/2025
    EGFR
    |
    EGFR expression • CDKN2A negative
    |
    cisplatin • TheraCIM (nimotuzumab)
    Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom (CIMAHOPE) (NCT03413579)
    Phase 3
    El Kendi Pharmaceuticals Manufacturing Company
    Completed
    Last update posted :
    08/25/2021
    Initiation :
    11/01/2015
    Primary completion :
    03/01/2020
    Completion :
    02/01/2021
    EGFR • BCL2
    |
    EGFR expression
    |
    cisplatin • carboplatin • vinorelbine tartrate • TheraCIM (nimotuzumab)
    Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (NCT03766178)
    Phase 2
    The First Affiliated Hospital of Zhengzhou Univ...
    Not yet recruiting
    Last update posted :
    07/07/2021
    Initiation :
    09/01/2021
    Primary completion :
    12/01/2022
    Completion :
    09/01/2023
    EGFR
    |
    AiRuiKa (camrelizumab) • TheraCIM (nimotuzumab)
    Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. (Carpp-1) (NCT04882462)
    Phase 2
    The First Affiliated Hospital of Soochow Univer...
    Not yet recruiting
    Last update posted :
    05/12/2021
    Initiation :
    05/01/2021
    Primary completion :
    11/30/2021
    Completion :
    12/31/2022
    PD-L1
    |
    Tyvyt (sintilimab) • TheraCIM (nimotuzumab)
    EGFR Monoclonal Antibody for Advanced Gastric Cancer (NCT04136600)
    Phase 2
    Shanghai Changzheng Hospital
    Recruiting
    Last update posted :
    12/30/2020
    Initiation :
    07/01/2019
    Primary completion :
    08/31/2021
    Completion :
    12/31/2021
    EGFR
    |
    EGFR amplification
    |
    Erbitux (cetuximab) • capecitabine • oxaliplatin • TheraCIM (nimotuzumab)
    By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC (NCT03557112)
    Phase 2
    Guiyang Medical University
    Unknown status
    Last update posted :
    11/02/2018
    Initiation :
    06/01/2018
    Primary completion :
    06/01/2021
    Completion :
    12/01/2021
    EGFR
    |
    cisplatin • TheraCIM (nimotuzumab)
    Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer (NCT03469531)
    Phase 2
    Zhujiang Hospital
    Unknown status
    Last update posted :
    08/13/2018
    Initiation :
    03/20/2018
    Primary completion :
    03/10/2021
    Completion :
    12/30/2021
    EGFR
    |
    cisplatin • TheraCIM (nimotuzumab)
    Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma (NIEGA) (NCT03400592)
    Phase 2
    Peking University
    Unknown status
    Last update posted :
    01/17/2018
    Initiation :
    06/01/2015
    Primary completion :
    06/01/2018
    Completion :
    06/01/2018
    EGFR
    |
    EGFR overexpression
    |
    irinotecan • TheraCIM (nimotuzumab)
    Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma (NCT03388372)
    Phase 2
    Biotech Pharmaceutical Co., Ltd.
    Completed
    Last update posted :
    01/03/2018
    Initiation :
    08/18/2010
    Primary completion :
    03/23/2017
    Completion :
    03/23/2017
    EGFR • MGMT
    |
    EGFR expression • EGFR positive • MGMT expression
    |
    temozolomide • TheraCIM (nimotuzumab)
    Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer (NCT02705612)
    Phase 2
    Air Force Military Medical University, China
    Unknown status
    Last update posted :
    03/10/2016
    Initiation :
    09/01/2015
    Primary completion :
    09/01/2016
    Completion :
    09/01/2018
    EGFR
    |
    EGFR expression • EGFR overexpression
    |
    cisplatin • TheraCIM (nimotuzumab)
    Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients (NCT01393080)
    Phase N/A
    Tianjin Medical University Cancer Institute and...
    Unknown status
    Last update posted :
    02/17/2016
    Initiation :
    03/01/2011
    Primary completion :
    12/01/2016
    Completion :
    12/01/2016
    EGFR
    |
    EGFR expression
    |
    carboplatin • paclitaxel • TheraCIM (nimotuzumab)
    Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients (NCT01939054)
    Phase 2
    Chinese Academy of Medical Sciences
    Unknown status
    Last update posted :
    06/04/2015
    Initiation :
    09/01/2013
    Primary completion :
    09/01/2015
    Completion :
    09/01/2016
    EGFR
    |
    docetaxel • capecitabine • TheraCIM (nimotuzumab)